{"id":"placebo-to-tocilizumab-iv","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Anemia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Increased risk of malignancies"}]},"_chembl":{"chemblId":"CHEMBL1237022","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Interleukin-6 is a cytokine that plays a key role in the inflammatory response. By blocking the interleukin-6 receptor, tocilizumab reduces inflammation and prevents tissue damage. This mechanism is particularly effective in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.","oneSentence":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:28:54.076Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"},{"name":"Giant cell arteritis"},{"name":"Carvastatin-induced giant cell arteritis"},{"name":"Polyarticular juvenile idiopathic arthritis"},{"name":"Systemic juvenile idiopathic arthritis"},{"name":"Cryopyrin-associated periodic syndrome"},{"name":"Macroscopic polyarteritis"}]},"trialDetails":[{"nctId":"NCT04412772","phase":"PHASE3","title":"Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS","status":"TERMINATED","sponsor":"Queen's Medical Center","startDate":"2020-06-12","conditions":"COVID-19","enrollment":20},{"nctId":"NCT07254637","phase":"PHASE2","title":"Tocilizumab in Chronic Inflammatory CPPD Disease","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04","conditions":"Calcium Pyrophosphate Deposition Disease","enrollment":80},{"nctId":"NCT01791842","phase":"PHASE2","title":"TOCILIZUMAB IN FIBROUS DYSPLASIA OF BONE","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2013-05-05","conditions":"Fibrous Dysplasia of Bone","enrollment":19},{"nctId":"NCT05168475","phase":"PHASE2","title":"Biologics in Refractory Vasculitis: A Trial of Biologic Therapy for Refractory Primary Non-ANCA Associated Vasculitis","status":"TERMINATED","sponsor":"Cambridge University Hospitals NHS Foundation Trust","startDate":"2021-07-14","conditions":"Giant Cell Arteritis, Takayasu Arteritis, Cogan Syndrome","enrollment":22},{"nctId":"NCT02049437","phase":"PHASE1, PHASE2","title":"AIDS 347: IL-6 Blockade in Treated HIV Infection","status":"COMPLETED","sponsor":"Case Western Reserve University","startDate":"2014-08","conditions":"HIV Infections","enrollment":34},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT04372186","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tocilizumab in Hospitalized Participants With COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2020-05-14","conditions":"COVID-19 Pneumonia","enrollment":377},{"nctId":"NCT04409262","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Participants With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-06-16","conditions":"COVID-19 Pneumonia","enrollment":649},{"nctId":"NCT02293837","phase":"PHASE2","title":"Tocilizumab (TCZ) in New-onset Type 1 Diabetes","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2015-03-12","conditions":"Type 1 Diabetes Mellitus, New-onset Type 1 Diabetes Mellitus, T1DM","enrollment":136},{"nctId":"NCT04356937","phase":"PHASE3","title":"Efficacy of Tocilizumab on Patients With COVID-19","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-04-20","conditions":"SARS-CoV 2","enrollment":243},{"nctId":"NCT04320615","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-04-03","conditions":"COVID-19 Pneumonia","enrollment":452},{"nctId":"NCT02336048","phase":"PHASE1","title":"A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2015-06-26","conditions":"B-Cell Chronic Lymphocytic Leukemia","enrollment":38},{"nctId":"NCT02034474","phase":"PHASE4","title":"Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia","status":"COMPLETED","sponsor":"New York State Psychiatric Institute","startDate":"2014-02","conditions":"Schizophrenia, Schizoaffective Disorder","enrollment":59},{"nctId":"NCT01034397","phase":"PHASE4","title":"A Study of Tocilizumab Plus Non-biological DMARD in Patients With Moderate to Severe Rheumatoid Arthritis and an Inadequate Response to Non-biological DMARDs","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-03","conditions":"Rheumatoid Arthritis","enrollment":54},{"nctId":"NCT00773461","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARD Therapy in Patients With Active Rheumatoid Arthritis.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-10-31","conditions":"Rheumatoid Arthritis","enrollment":209},{"nctId":"NCT00535782","phase":"PHASE3","title":"A Study of the Effect of Tocilizumab on Markers of Atherogenic Risk in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10-31","conditions":"Rheumatoid Arthritis","enrollment":132},{"nctId":"NCT01007435","phase":"PHASE3","title":"A Study of Tocilizumab as Monotherapy and in Combination With Methotrexate Versus Methotrexate in Patients With Early Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-10-31","conditions":"Rheumatoid Arthritis","enrollment":1162},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT00106574","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + DMARD Therapy on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-04","conditions":"Rheumatoid Arthritis","enrollment":1220},{"nctId":"NCT00106522","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis Currently on Methotrexate Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-05","conditions":"Rheumatoid Arthritis","enrollment":499},{"nctId":"NCT01661140","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate in Patients With Severe Active Rheumatoid Arthritis, Comparing Tapering Versus Maintaining the Methotrexate Dosage","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2012-09","conditions":"Rheumatoid Arthritis","enrollment":427},{"nctId":"NCT00642460","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Active Systemic Juvenile Idiopathic Arthritis (JIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Juvenile Idiopathic Arthritis","enrollment":112},{"nctId":"NCT01034137","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate in Combination or as Monotherapy in Treatment-Naïve Patients With Early Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-01","conditions":"Rheumatoid Arthritis","enrollment":317},{"nctId":"NCT01194414","phase":"PHASE3","title":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":1262},{"nctId":"NCT01991990","phase":"PHASE4","title":"A Pharmacodynamic Study to Evaluate Neutrophil Distribution Kinetics and Function Following Single-Dose RoActemra/Actemra (Tocilizumab) in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05","conditions":"Healthy Volunteer","enrollment":18},{"nctId":"NCT01587989","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) With or Without Methotrexate in Patients With Mild to Moderate Rheumatoid Arthritis With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-02","conditions":"Rheumatoid Arthritis","enrollment":77},{"nctId":"NCT01399697","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) in Combination With Methotrexate Versus RoActemra/Actemra Monotherapy in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-09","conditions":"Rheumatoid Arthritis","enrollment":261},{"nctId":"NCT00845832","phase":"PHASE2","title":"A Study of Combination Treatment With MabThera (Rituximab) and RoActemra (Tocilizumab) Versus RoActemra in Patients With Rheumatoid Arthritis With an Incomplete Response to Methotrexate","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":24},{"nctId":"NCT00977106","phase":"PHASE3","title":"TORPEDO Study: A Study on Rapid Effect of Tocilizumab in Patients With Rheumatoid Arthritis With an Inadequate Response to Disease-Modifying Antirheumatic Drugs (DMARDs) or Anti-TNF","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-06","conditions":"Rheumatoid Arthritis","enrollment":103},{"nctId":"NCT00810199","phase":"PHASE3","title":"A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-03","conditions":"Rheumatoid Arthritis","enrollment":556},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96},{"nctId":"NCT00106535","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Prevention of Structural Joint Damage in Patients With Moderate to Severe Active Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2005-01","conditions":"Rheumatoid Arthritis","enrollment":1196},{"nctId":"NCT01209702","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) in Patients With Ankylosing Spondylitis Who Have Failed Treatment With NSAIDs","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Spondylitis, Ankylosing","enrollment":306},{"nctId":"NCT01258712","phase":"PHASE3","title":"Study of Tocilizumab in Combination With Methotrexate for Treatment of Moderate to Severe Rheumatoid Arthritis Patients","status":"COMPLETED","sponsor":"Chugai Pharma Taiwan","startDate":"2010-12","conditions":"Rheumatoid Arthritis (RA)","enrollment":86},{"nctId":"NCT00531817","phase":"PHASE3","title":"A Study of Tocilizumab in Combination With DMARDs in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2007-10","conditions":"Rheumatoid Arthritis","enrollment":619},{"nctId":"NCT00106548","phase":"PHASE3","title":"A Study to Assess the Effect of Tocilizumab + Methotrexate on Signs and Symptoms in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"","conditions":"Rheumatoid Arthritis","enrollment":623}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"placebo to tocilizumab IV","genericName":"placebo to tocilizumab IV","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab is an interleukin-6 receptor antagonist that inhibits the inflammatory response by blocking the action of interleukin-6. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis, Giant cell arteritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}